FDA: mifepristone review won't be done until March

The Food and Drug Administration (FDA) has announced in a Wednesday court filing that its safety review of the abortion medication mifepristone will not be completed until March.

Alongside the timeline disclosure, the agency stated that it will not implement any new restrictions on the pill prior to the completion of the review.

According to the filings, this delay and the absence of immediate restrictions are expected to further anger anti-abortion activists who have faced ongoing legal and political setbacks.